Please assess the completion status of the following clinical trial:

Trial Title: Luteal Phase Support During Frozen Embryo Transfer Cycle

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with surplus embryos undergone infertility treatment cycles (e.g. OHSS, inadequate endometrium, surplus frozen embryo from any cause)~2. Age 21-37 years~3. Normal BMI (18.5 \<BMI \<30)~4. IVF / ICSI or IVF or ICSI cycles with antagonists or agonists protocols~5. Frozen embryos on 2-3 days~Exclusion Criteria:~1. Endometrial thickness ≤7mm~2. Egg Donors~3. Surrogacy~4. Male factor infertility with azoospermia~5. Age \<37 years old~6. Hydrosalpinx~7. Uterine anomalies~8. Myoma with a compression effect or submocusa myoma~9. PGD~10. Blastocyst embryo transfer, ZIFT and GIFT

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 37 Years
- Healthy Volunteers: t

Study Arms:
- FET cycle, discontinue estradiol after 6 gestational weeks (Type: EXPERIMENTAL): In patients 35 days after embryo transfer and observation of gestational sac with heart beat (6 weeks of pregnancy) by ultrasound, exogenous estrogen will discontinued while progesterone will remain daily use until twelfth week of pregnancy.
- FET cycle, continue estradiol till 12 gestational weeks (Type: ACTIVE_COMPARATOR): Control group receive 6 mg oral estrogen and 100 mg intramuscularly progesterone until 12 week of pregnancy.

Based on this trial design, predict the completion outcome and termination type (if applicable).